Gormez, S.Gumusel, H. K.Ekicibasi, E.Degirmencioglu, A.Paudel, A.Akan, G.Atalar, F.Erdim, R.Eroglu, E.Dagdelen, S.Sariguzel, N.Kirisoglu, C. E.Pamukcu, B.2023-02-212023-02-212021-01-0110.4149/BLL_2021_093https://hdl.handle.net/11443/2516http://dx.doi.org/10.4149/BLL_2021_093OBJECTIVES: Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission. BACKGROUND: Coronavirus disease-2019 (COVID-19) predisposes patients to arterial and venous thrombosis. METHODS: In this retrospective, multicentre and observational study we analysed the data of 308 confirmed COVID-19 patients with normal D-dimer levels at initial admission. After propensity score matching (PSM) patients were groupedGroup 1patients who received LMWH with D-dimer <= 0.5 mg/L, Group 2patients who received LMWH after D-dimer levels exceeded 0.5 mg/L, and Group 3patients who did not receive LMWH. RESULTS: After PSM, each group comprised 40 patients. The patients in Group1 had the best clinical outcomes compared to the other groups. Group 3 had the worst clinical outcomes (p< 0.005). The benefit of LMWH increased with early prophylactic therapy especially when started while the D-dimer levels were <= 0.5 mg/L. CONCLUSION: Our results strongly suggest that proactive LMWH therapy improves clinical outcomes in hospitalized COVID-19 patients even with normal D-dimer levels (<= 0.5 mg/L) (Tab. 3, Fig. 2, Ref. 34). Text in PDF www.elis.skCOVID-19SARS-CoV-2thrombosisantithrombotic therapylow-molecular-weight heparinD-dimerenoxaparinArticleWOS:000678623200009